Search
forLearn
5 / 801 resultsResearch
5 / 841 resultsresearch Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis
WNT signaling is crucial for starting mammary gland development.
research FGF signaling is required for initiation of feather placode development
FGF signaling is crucial for starting feather development in chicken embryos.
research Genetic basis of skin appendage development
Hair, teeth, and mammary glands develop similarly at first but use different genes later.
research Prenatal hair development: Implications for drug exposure determination
Neonatal hair can help determine drug exposure during pregnancy.
research Expression of Hex during feather bud development
Hex gene plays a crucial role in starting feather development in chick embryos.
Community Join
5 / 1000+ resultscommunity Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Anyone heard of scube3? And other emerging treatments?
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
community Why doesn't phase 3 of PP405 start straight away?
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.